Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Evotec extends research agreement with Cubist Pharmaceuticals
April 2010
SHARING OPTIONS:

HAMBURG, GermanyŚEvotec AG has an extended a research agreement with Cubist Pharmaceuticals Inc. to the end of this year. The original agreement, signed in July 2009, focused on progressing drug discovery programs using Evotec's fragment-based drug discovery platform. Under the contract extension, Evotec will provide additional fragment-based drug discovery expertise using its proprietary platform, EVOlution, which includes fragment screening, structural biology and protein crystallography, to discover and profile novel compounds against additional antibacterial targets selected by Cubist. No financial details are disclosed.


Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.